Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Addex Therapeutics Ltd.ADXN · Entity 8301 | Director · CHIEF MEDICAL OFFICER | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Addex Therapeutics Ltd.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 785,976 |
Ending reported balance
After 2026-09-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Disposition to issuer · Disposed 392,837 · Balance 393,139 F1: Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026 Row 2 · 2026-09-02 · Grant · Acquired 392,837 · Balance 785,976 F1: Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026 |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2034-01-07 | Direct | 0 |
Reported balance
After 2026-09-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-02 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F2: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2034-01-07 | Direct | 50,000 |
Reported balance
After 2026-09-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-02 · Grant · Acquired 50,000 · Balance 50,000 F3: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F2: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026
F2: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
F3: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 20:05 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105496 · tm2624769-7_4seq1.xml · derivative · entry 4 Mills Roger · CIK 0001368190 · Director · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-07 F3 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F2 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:05 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001104659-26-105496 · tm2624769-7_4seq1.xml · derivative · entry 3 Mills Roger · CIK 0001368190 · Director · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2034-01-07 F3 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F2 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:05 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantCommon Stock | 392,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105496 · tm2624769-7_4seq1.xml · nonDerivative · entry 2 Mills Roger · CIK 0001368190 · Director · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 785,976 F1 · kind: Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026 F1 · price: Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026 Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:05 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerCommon Stock | 392,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105496 · tm2624769-7_4seq1.xml · nonDerivative · entry 1 Mills Roger · CIK 0001368190 · Director · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,139 F1 · kind: Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026 F1 · price: Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.